Anti-OX40 Therapy

Imagine a cancer therapy that revs up the immune system to recognize and destroy cancer, similar to how stepping on the gas pedal revs up a car’s engine to accelerate. Now imagine this treatment also builds immunity to that cancer, preventing it from coming back. That’s the potential we’re seeing in a cancer-fighting antibody anti-OX40, which was developed and tested in humans for the first time at Providence Cancer Center. Anti-OX40 is rapidly gaining traction as an innovative way to potentially treat cancer.

Learn more ›

Types of Cancer Treated with anti-OX40

While anti-OX40 has the potential to improve treatment for any type of cancer, our research and clinical trials to date have focused on:

  • Head and neck cancer
  • Melanoma (skin cancer)
  • Breast cancer
  • Colorectal cancer
  • Kidney cancer
  • Prostate cancer

Our goal is to add anti-OX40 to other treatments to help boost responses in tumors that were previously resistant to immunotherapy.

How OX40 Works

OX40 is a protein with powerful cancer-fighting properties found on the surface of certain T-cells, the white blood cells that help the immune system fight diseases. Providence scientists engineered an antibody to this protein, called anti-OX40, which activates T-cells to attack cancer cells.

Early research results spurred Providence to launch the world’s first clinical trial of anti-OX40 in humans. In that trial, anti-OX40 shrank tumors in 12 of 30 patients studied. Read the study abstract.

Clinical Trials

In new studies, we are combining anti-OX40 with other treatments that release the brakes on the immune system, in much the same way that anti-OX40 hits the gas, to maximize the activity of immune cells. One study, for example, combines anti-OX40 with stereotactic body radiation therapy (SBRT) in people with metastatic breast cancer.

View a list of our current OX40 clinical trials ›

Latest news

View All